Señales en vivo de BLU | Maximiza tus Ganancias con Getagraph.com

Live Chart Being Loaded With Signals

Commentary (28 jun 2023 @ 15:59):

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications...

Stats
Volumen de hoy	2.84M
Volumen promedio	5.38M
Capitalización de mercado	1.87B
EPS	$0 ( 2024-03-19 )
Próxima fecha de ganancias	( $0 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-20.20
ATR14	$0.119 (0.81%)

Volumen Correlación

Largo: 0.19 (neutral)

Corto: 0.64 (weak)

Signal:(78.88) Neutral

BELLUS Health Inc Correlación

10 Correlaciones Más Positivas
SRRA	0.976
SCPL	0.973
DTSS	0.968
CYCN	0.966
NISN	0.961
BWC	0.959
MEDP	0.958
HCSG	0.955
TESS	0.955
MNTV	0.954

10 Correlaciones Más Negativas
QDEL	-0.976
LIZI	-0.953
CYAN	-0.95
SSRM	-0.943
JCTCF	-0.943
CRUS	-0.942
BRQS	-0.941
MTEX	-0.939
VRAY	-0.935
CFBK	-0.934

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

BELLUS Health Inc Correlación - Moneda/Commodity

0.43
( neutral )

0.66
( moderate )

-0.21
( neutral )

-0.19
( neutral )

-0.54
( weak negative )

0.67
( moderate )

BELLUS Health Inc Finanzas

Annual	2022
Ingresos:	$16 000.00
Beneficio Bruto:	$-3.51B (-21 967 104.08 %)
EPS:	$-0.660

FY	2022
Ingresos:	$16 000.00
Beneficio Bruto:	$-3.51B (-21 967 104.08 %)
EPS:	$-0.660

FY	2021
Ingresos:	$16 000.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-1.207

FY	2020
Ingresos:	$15 000.00
Beneficio Bruto:	$0.00 (0.00 %)
EPS:	$-0.540

Financial Reports:

No articles found.

BELLUS Health Inc

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada.

Actualizaciones en tiempo real para BELLUS Health Inc [BLU]

Upcoming Earnings Alert